Retrospective analysis on the efficacy of sunitinib/sorafenib in combination with dendritic cells-cytokine-induced killer in metastasis renal cell carcinoma after radical nephrectomy.

Abstract

OBJECTIVE:

Sunitinib/sorafenib (SU/SO), dendritic cells (DCs), or DC-cytokine-induced killer (CIK) could significantly prolong progression-free survival (PFS), 3-year overall survival (OS), or 5-year OS for patients with metastatic renal cell carcinoma (mRCC). We retrospectively analyzed the clinical efficacy between SU/SO combined with DC-CIK and SU/SO monotherapy in treating renal cell carcinoma (RCC) patients with metastasis after radical nephrectomy.

MATERIALS AND METHODS:

All patients (n = 34) with postoperative mRCC in our hospital from January 2009 to January 2014 were received either SU/SO monotherapy (Group 1, n = 15) or in combination with DC-CIK (Group 2, n = 19). A retrospective study was based on the primary endpoint (PFS) and secondary endpoint (OS).

RESULTS:

At a median follow-up of 19.5 months, in Group 2, as compared with in Group 1, the median PFS was significantly longer (28.0 vs. 11.0 months, P = 0.03). Moreover, the 3-year OS was higher (57.1% vs. 28.6%). The cases of progressive diseases (PDs) and deaths were less in Group 2 than that in Group 1 (PD: 8 vs. 9, deaths: 3 vs. 5); however, the cases of stable diseases were more (11 vs. 6). In addition, the 3-year OS was higher in SU + DC-CIK group than that in SO + DC-CIK group (63.36% vs. 50%). There was no significant difference for PFS between SO + DC-CIK group and SU single agent group.

CONCLUSIONS:

SU/SO with DC-CIK could significantly prolong the median PFS, improve the 3-year OS rate, prolong the 3-year OS. It is likely to be a new approach for mRCC after radical nephrectomy.

• Authors: Hai-Xing Mai, Guo-Hui Mei, Fei-Long Zhao, Bo-Tao Li, Yong-Yong Tang, Bin Zhang, Xiao-Jie Xu, Li-Jun Chen
• Journal: Journal of cancer research and therapeutics (J Cancer Res Ther) Vol. 14 Issue Supplement Pg. S427-S432 (Jun 2018) ISSN: 1998-4138 [Electronic] India
• PMID: 29970701 (Publication Type: Journal Article)

Chemical References

• Cancer Vaccines
• Indoles
• Phenylurea Compounds
• Pyrroles
• Niacinamide
• Sorafenib
• Sunitinib

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Cancer Vaccines
• Carcinoma, Renal Cell (immunology, mortality, pathology, therapy)
• Combined Modality Therapy
• Cytokine-Induced Killer Cells (immunology, metabolism)
• Dendritic Cells (immunology, metabolism)
• Female
• Humans
• Immunotherapy, Adoptive (methods)
• Indoles (administration & dosage)
• Kidney Neoplasms (immunology, mortality, pathology, therapy)
• Male
• Middle Aged
• Neoplasm Metastasis
• Neoplasm Staging
• Niacinamide (administration & dosage, analogs & derivatives)
• Phenylurea Compounds (administration & dosage)
• Postoperative Care
• Pyrroles (administration & dosage)
• Retrospective Studies
• Sorafenib
• Sunitinib
• Survival Analysis
• Treatment Outcome